newsfilter
← Latest News
ClinicalTrials.gov·

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis - NCT04856891

Proportion of Responders, where a responder is a patient achieving a mean peak duodenal eosinophil count ≤15 cells/3 duodenal hpf., Mean absolute change in TSS as measured by the PRO questionnaire., Percent change in tissue eosinophils, (and 5 more...)